SGLT2 Inhibitors 2016: Year-End News Roundup


SGLT2 inhibitors made diabetes headlines this year by gaining FDA approval for cardiovascular indication. We highlight this news and more for 2016.

We present a review of developments in SGLT2 inhibitors for the year 2016 – from the EMPA-REG OUTCOMES trial to successful dual therapy treatments to FDA advisories and safety guidelines.See the slide legends for links to the article summaries.

Related Videos
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
Alexandra Louise Møller, MS, PhD | Credit: LinkedIn
A panel of 5 experts on Cushing's syndrome
A panel of 5 experts on Cushing's syndrome
Optimizing Diabetes Therapies with New Classifications
Vlado Perkovic, MBBS, PhD | Credit: George Institute of Global Health
Should We Reclassify Diabetes Subtypes?
What Should the American Academy of Physician Associates Focus on in 2025?
GLP-1 Agonist Safety Risks and Obesity Stigma with Kevin Peterson, MD, MPH
Video 8 - "Pathophysiology of Hypercortisolism"
© 2024 MJH Life Sciences

All rights reserved.